Dose Response Study of Patients With Erythematous Rosacea

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

August 31, 2010

Conditions
Erythematous (Type One) Rosacea
Interventions
DRUG

V-101

Cream QD

OTHER

vehicle

Cream QD

Trial Locations (7)

33140

Baumann Cosmetic & Research Institute, Miami Beach

40202

Dermatology Specialists Research, Louisville

48038

DBA Michigan Center for Skin Care Research, Clinton Twp

78759

DermResearch, Inc., Austin

87106

Academic Dermatology Associates, Albuquerque

92123

Therapeutics Clinical Research, San Diego

97223

Oregon Medical Research Center, PC, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Accenture

INDUSTRY

lead

Vicept Therapeutics, Inc.

INDUSTRY

NCT01186068 - Dose Response Study of Patients With Erythematous Rosacea | Biotech Hunter | Biotech Hunter